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ABSTRACT
Thermal and magnetically sensitive polymers are a new class of materials with unique properties
suitable for applications in drug delivery. Specifically, these polymers can be combined with a drug
reservoir to make a drug delivery device that can be triggered externally. Such a device could be
implanted subcutaneously and allow for temporal control of drug release and localized delivery. Current
experiments have shown that a prototype device is capable of delivering both small and large molecule
drugs. Attractive medical applications for this technology were discovered and their respective markets
examined. Additionally, the scientific literature and intellectual property in this field were analyzed for
competing technologies that would hinder development of this invention. Novel attributes of this
technology were also identified and specific competitive advantages made evident.
To facilitate the commercialization of this novel technology, a business model has been proposed that
identifies possible risks and provides strategies for overcoming them. Using this model, a timeline for
future research and development has been constructed that traces the technology from its current state
to a final product that can be launched commercially. The requirements for regulatory approval have
also been investigated and a plausible manufacturing process has been established. Furthermore, a cost
model and pricing analysis has been conducted to determine if a viable business proposition around this
technology can be made.
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Senior Associate in Critical Care Medicine, Children's Hospital Boston
ACKNOWLEDGEMENTS
To my parents, Jerome and Agnes Edward. Thank you for all of your
support and for the sacrifices you have made throughout my life to help
me succeed. You have always encouraged me to do my best, to never
give up, and to work hard. You have taught me to be responsible and
have always been there for me when I needed it most.
To my brother, Justin Edward. Thank you for always being there and for
your encouragement.
To all of my friends - those from high school, my undergraduate years
at Johns Hopkins, and at MIT - Thanks for always supporting me and
being there through good times and bad.
And finally, to Dr. Daniel Kohane, Dr. Todd Hoare, and Dr. Robert
Langer. Thank you for sharing your exciting research with me and for
giving me the opportunity to work with you. This thesis would not have
been possible without your help and guidance.
TABLE OF CONTENTS
TABLE OF CONTENTS ..................................................................................................................... 4
1. INTRODUCTION ..................................................................................................................... 8
2. BACKG RO U N D ............................................................................................................................ 9
2.1 D rug D elivery................................................................................... ....................................... 9
2.2 Unmet Need.............................................................. .............. ....................... 13
3. TECHNOLOGY ...................................................................................................................... 15
3.1 Polymer Membrane ........................................ .. ........................................... 15
3.2 Delivery Device ........................ ...................... .......................................................... 17
3.3 Progress to Date................................................................................................................ 19
3.4 Novel Attributes of this Invention........................................... ............................................. 20
3.5 Competing Technologies.......................................... 21
3.6 Key Technical Barriers ......................................... .................... ........................................... 22
4. POTENTIAL APPLICATIONS & MARKET ANALYSIS ........................................... .......... 24
4.1 Potential Applications ............................................ ........................................................... 24
4.2 Market Analysis: Pain Management ..................................................................................... 26
4.3 M arket A nalysis: Cancer........................... .... ........ .... ................................................. 28
4.4 Market Analysis: Epilepsy .............................................................................. 31
4.5 Market Analysis: Insulin Delivery (Diabetes) .......................... ................ 33
4.6 Competitive Advantage (Pain Management, Cancer, & Epilepsy Applications) ...................... 36
5. INTELLECTUAL PROPERTY..................................................................................................... 38
5.1 Current Status of Intellectual Property................................ ...................... 38
5.2 Competing Patents......................................... ............................ 38
5.3 Intellectual Property Strategy ........................... ......... .............................. 42
4
6. BUSINESS M ODEL ................................................................................... ............................. 44
6.1 Paths to Commercialization ................................................... 44
6.2 Proposed Business M odel ........................................................................................................... 45
6.3 Value Chain ................................................................................................................................. 46
6.4 Key Decision M akers ................................................................................................................... 48
7. DEVELOPM ENT PLAN ................................................... ........................................................ 50
7.1 Regulatory Approval ................................................................................................................... 50
7.2 M anufacturing ............................................................................................................................ 55
7.3 Developm ent Tim eline ................................................................................................................ 57
8. COST M ODEL ................................................................................... .................................... 59
8.1 Pre-Com mercial Costs (Academ ic Laboratory) ..................................................................... 59
8.2 Development Costs .......................................................... 59
8.3 Pricing........................................... 62
9. INVESTM ENT .................................................................................... ................................... 66
9.1 Investment Required ...................................................... ........................................ 66
9.2 Sources of Funding .......................................... 67
9.3 Com parables ..... ............................................................................................................ 69
10. RISK ASSESSM ENT ............................................................................... ................................ 71
11. CONCLUSIONS .................................................................................. ................................... 73
12. REFERENCES ................................................................................... ..................................... 75
List of Figures
Figure 1: Drug Delivery (DD) product chronology................................................................................. 9
Figure 2: Levels of drug in the blood using traditional dosing versus controlled-release dosing ........... 11
Figure 3: Mechanism of drug release from polymer membrane............................ ... ............ 16
Figure 4: Chemical structures of NIPMAM, NIPAM and ethyl cellulose ......................................... 17
Figure 5: Prototype of drug delivery device........................................... ............................................... 18
Figure 6: Prototype of delivery device with antenna ..................................................................... 19
Figure 7: Biocompatibility of membranes implanted in vivo..................................... ............ 19
Figure 8: Sodium fluorescein flux results from prototype drug delivery device ..................................... 20
Figure 9: Millimeter-sized reservoirs in prototype MicroCHIPS drug delivery device ............................. 22
Figure 10: Insertion of Ventriculo-Peritoneal (VP) shunt for draining cerebrospinal fluid (CSF) ............ 31
Figure 11: Value chain ............................................... 48
Figure 12: Schematic of batch reactor with single external cooling jacket ...................................... 55
Figure 13: Technology developm ent tim eline ............................................................................................ 58
List of Tables
Table 1: Number of drug delivery technologies divided by category.............................. ......... 10
Table 2: Commonly used families of polymers in drug delivery systems ........................................ 12
Table 3: Commonly used environmentally-sensitive hydrogels in drug delivery systems ...................... 13
Table 4: Summary of competition in pain management market..................................................... 28
Table 5: U.S. five-year cancer relative survival rates (1996-2003) ....................................... ....... 29
Table 6: Areas of greatest development in cancer therapies ......................................... .......... 30
Table 7: Summary of competition in epilepsy market.................................................................... 32
Table 8: Summary of the three types of diabetes .................................................................................. 33
Table 9: Summary of competition in insulin delivery market........................................................ 35
Table 10: Com peting patents........ ............................................................................................. 39
Table 11: Combination product responsibilities for lead FDA center................................ ........ 51
Table 12: Combination-product examples and FDA center jurisdiction ......................................... 51
Table 13: Comparison of CDRH and CDER combination product review teams......................................... 51
Table 14: Common preclinical testing inadequacies for combination product submissions .................. 53
Table 15: Definition of chemistry, manufacturing, controls testing components ................................... 54
Table 16: Manufacturing steps for making remote-controlled drug delivery device .............................. 56
Table 17: Future investment needed to reach preclinical trials ........................................ ........ 59
Table 18: Material costs for remote-controlled drug delivery device ...................................... ............ 60
Table 19: Per patient costs for clinical trials in six disease areas.................................... ...... 61
Table 20: Startup costs........... ..................................................................................................... 62
Table 21: Summary of pricing analysis with cost breakdown ......................................... .......... 63
Table 22: Summary of assumptions in price analysis .................................................... 64
Table 23: Price comparison of various pain management therapies ...................................... ............. 64
Table 24: Price comparison of various cancer therapies ...................................................................... 65
Table 25: Price comparison of various epilepsy therapies .......................................... ............ 65
Table 26: Total investment needed to bring technology to completion of preclinical trials .................. 66
Table 27: M icroCHIPS, Inc. investm ent history ............... ...................................................................... 67
Table 28: IPO and M &A com parables ...................................................................... ............................. 70
Table 29: Critical risks facing successful commercialization of this technology ....................... ......... 72
1. INTRODUCTION
From oral tablets to drug eluting stents, drug delivery technologies have played an integral role in
advancing the field of medicine and improving the quality of human life. Research in drug delivery has
resulted in novel ways to administer pharmaceuticals in a safer and more efficacious manner, and has
also led to medical therapies that increase patient compliance and convenience. Two areas that have
seen less advancement due to a host of technical challenges, however, have been temporal control of
drug release and localized delivery. The few drug delivery technologies that exist with these
characteristics are very limited in their applications.
Recent developments by Dr. Daniel Kohane and Dr. Todd Hoare from the Langer laboratory in the
Department of Chemical Engineering show promise in solving this problem. Dr. Kohane and Dr. Hoare
have developed a thermal and magnetically sensitive polymer for use in a drug delivery device that
could be triggered externally. Such a device would be implanted in the body subcutaneously and allow
drug to be released at specific times and for specific durations. Current experiments have shown that
the device is capable of delivering both small molecule drugs as well as macromolecular drugs such as
insulin. The following thesis aims to identify attractive applications for this technology as well as the
steps needed to bring this invention from an academic laboratory into commercial use as a drug delivery
device. Additional topics that will be addressed include a discussion of intellectual property,
manufacturing and regulatory hurdles that need to be overcome as well as possible paths to
commercialization.
2. BACKGROUND
2.1 Drug Delivery
The field of drug delivery was launched in the 1950s with the invention of tablets and capsules for
packaging and delivering pharmaceutical agents. Since then, the field has seen enormous technological
growth, from the invention of nasal and transdermal products in the late 1970s and early 1980s, to more
recent drug delivery products that incorporate nanoparticles and adviral vectors'. A complete drug
delivery product timeline can be seen in Figure 1. At present, the number of commercial drug delivery
technologies is in the thousands and can be divided into nine main categories: oral delivery, skin
delivery, transmucosal delivery, inhalation, injectables, brain delivery, medical devices, platform
technologies, and other delivery mechanisms 2. A chart depicting the number of drug delivery
technologies in each of these categories can be found in Table 1.
Furthermore, this vast technological growth has been accompanied by an equivalent growth in global
drug delivery product and service revenues, which are currently over $50 billion. Today, drug delivery
technologies are used in almost half of all marketed pharmaceutical products worldwide and almost
one-third of all pipeline products in biotechnology & pharmaceutical companies. Additionally, 38% of
the top pharmaceutical products sold globally incorporated drug delivery technologies in 2006
amounting to sales of over $115 billion .
DD PRODUCT CHRONOLOGY
YEAR
Figure 1: Drug Delivery (DD) product chronology1
Table 1: Number of drug delivery technologies divided by category'
Drug Delivery Technologies
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Although the field of drug delivery is well established and has resulted in countless technologies that
have improved the efficacy and safety of pharmaceutical products, there are still many unmet needs.
Current challenges include developing delivery systems that can reduce the toxicity of drugs, increase
their absorption into the body, and improve their release profile2. Additionally, many newer therapies,
such as some protein and DNA drugs, are not compatible with traditional drug delivery methods. In
order to solve these problems, current research efforts have focused on controlled-release and targeted
drug delivery. Controlled- release technologies involve developing systems that allow for slow delivery
of compounds over hours to years. This slow release is typically achieved by encapsulating drugs within
biodegradable polymer matrices. Drug is then released from the system through diffusion, polymer
degradation, or swelling followed by diffusion. The advantages of this method are they allow drug levels
to be maintained within a desired range (see Figure 2) and they minimize the amount of dosing
required3 .
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Figure 2: Levels of drug in the blood using traditional dosing versus controlled-release dosing4
Research in targeted drug delivery is aimed at finding ways to target drug molecules to a particular site
of action. This approach reduces the chance of side effects since it minimizes the exposure of outside
tissues and organs to the drug being used. An example of where targeted delivery is desirable is cancer
therapy since the chemotherapeutic agents used to treat cancer are toxic to both healthy and malignant
cells. One way in which scientists have been trying to achieve targeted drug delivery in the laboratory is
through nanotechnology. Nanotechnology includes a range of sub-micron systems such as
nanoparticles, nanocapsules, lipid complexes, polymeric micelles, and dendrimers. Nanotechnology is
important to targeted drug delivery because the surface of nanoparticles can be modified to increase
the solubility of drugs as well as their bioavailability. Specifically, nanoparticle surfaces can be made to
carry a specific motif that can be recognized by cell membrane receptors to achieve targeting.
Nanoparticles can also be made to entrap or encapsulate small and large moleculess.
Both controlled-release and targeted drug delivery rely on specific formulations of polymers that are
biocompatible and have unique physical properties. Some of the most commonly used families of
polymers in drug delivery research can be found in Table 2.
Traditional Dosing
Table 2: Commonly used families of polymers in drug delivery systems4
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Additionally, more and more scientists have been using environmentally sensitive systems to achieve
controlled-release and/or targeted drug delivery. These systems are typically based on "intelligent"
hydrogels, which will retain their contents until a specific environmental stimulus is applied or removed.
At this point, the hydrogel will either swell or collapse to release drug into its surroundings. Some of the
most commonly used environmentally-sensitive hydrogels can be found in Table 3.
Table 3: Commonly used environmentally-sensitive hydrogels in drug delivery systems4
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2.2 Unmet Need
Despite all the research in controlled and targeted drug delivery, there are currently very few drug
delivery technologies that allow for both local delivery and controlled-release that can be turned on and
off repeatedly. Most commercial drug delivery devices that allow for local delivery, release drug
continuously and either show continuously declining or near-constant release of drug over time.
Although oral delivery of drugs allows for temporal control, most drugs taken orally do not allow for
local delivery and instead must be delivered systemically. Drugs delivered systemically have a host of
problems because they are released into the bloodstream and travel throughout the body. Since a single
drug will affect tissues and organs differently, systemic drugs have a higher chance of side effects. In the
case of narcotics, for example, the drug will travel to the brain, leading to dependence and causing an
II
altered mental state. Finally, drugs delivered systemically must be administered at higher doses since
very little of the drug actually reaches the area of interest.
3. TECHNOLOGY
3.1 Polymer Membrane
As mentioned, the core technology in this invention is a novel composite polymer membrane for use in a
drug delivery device that can be triggered remotely. It is responsible for the device's thermal and
magnetic sensitivity and controls the release of drug into the body.
This polymer membrane has three main components:
1. Polymer backbone
2. Thermosensitive microgel
3. Heat transducer (gold colloid or magnetic ferrofluid)
The membrane is cast in such a way that the pores of the membrane are filled with the thermosensitive
microgels, which have diameters of around 800 nm in the swollen drug-containing state (T < 37°C) and
diameters of around 250 - 300 nm in the collapsed drug-releasing state (T > 42'C). The magnetic or
metallic particles are incorporated throughout the bulk of the membrane so they do not interfere with
the swelling of the microgels.
The resulting polymer membrane works as follows:
1. An applied magnetic or electromagnetic field is absorbed by the membrane and causes the
inorganic components of the membrane (gold nanoparticles or ferrofluid) to heat up. An
oscillating magnetic field creates heat via energy level transitions due to dipole switching in the
ferromagnetic material. In the case of microwaves, heat is created via resistive heating of the
conductive gold nanoparticles.
2. The heat created is transferred from the inorganic components to the microgels adjacent to
them in the membrane design. This causes the thermosensitive microgels to undergo a
deswelling volume phase transition and collapse.
3. The reduced volume of the microgels increases the free volume within the fixed-size pores of
the polymer membrane (defined by the polymer backbone). This opening of the pores allows
drug to diffuse through the membrane.
4. Removal of the electromagnetic radiation or the oscillating magnetic field causes the device to
cool by thermal conduction. This in turn causes the thermosensitive microgel to swell back to its
original volume and fill the pores of the membrane. As the pores close, the drug diffusion rate
decreases to below therapeutic values.
The mechanism by which external radiation opens the pores of the polymer membrane for drug release
is summarized in Figure 3 below.
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Figure 3: Mechanism of drug release from polymer membrane
Constructing the Membrane
The thermosensitive microgel used in this polymer membrane is made from N-isopropylmethacrylamide
(NIPMAM) and N-isopropylacrylamide (NIPAM). The chemical structures for these polymers can be seen
in Figure 4. Both NIPAM and NIPMAM are synthetic aqueous microgels that are temperature sensitive6.
Temperature sensitivity can be adjusted by copolymerization with acrylamide derivatives such as N,N-
dimethylacrylamide (DMA)7 .A NIPMAM-NIPAM copolymer microgel was chosen because it was found to
deswell more and over a narrower temperature range compared to other N-isopropylacrylamide-based
microgels. This copolymer microgel is an enabling technology that has never been reported before and
is the integral component that gives this membrane its unique properties for use in drug delivery
devices.
In order to initiate opening and closing of the membrane pores (deswelling /swelling of the
thermosensitive microgels), a heat transducer is used. For magnetic sensitivity, a ferrofluid made from
magnetite (Fe3O4) is used, and for electromagnetic sensitivity, gold nanoparticles (AuCI 3) are used. The
last major component of the polymer membrane is the polymer backbone, which constitutes the bulk of
the membrane and is made from ethyl cellulose (See Figure 4). This membrane support acts as a scaffold
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and has pores, which are filled with the NIPMAM-NIPAM copolymer microgel. Ethyl cellulose, a
derivative of the organic compound cellulose found in plants, serves this role well since it forms a tough
flexible film that is wear resistant 8. Additionally, ethyl cellulose is often used in medical applications as a
tablet binder, and is thus safe for implantation into the body 9. Ethyl cellulose is also an excellent
insulator and serves to trap the heat generated by electromagnetic radiation to ensure that the region
directly outside the polymer membrane does not heat up significantly.
In order to make the polymer membrane, the thermosensitive microgel, heat transducer, and ethyl
cellulose are combined by physical mixing. The resulting polymer membrane is a tough flexible film that
is similar in texture to its main component, ethyl cellulose.
CHS
CH2--C CH2=CH
CI O C= O H oR cO
NH NH
I .O I . O o H
H3C Cit3  HnC %-CH3
NIPMAM'1  NIPAM'1  Ethyl cellulose9
Figure 4: Chemical structures of NIPMAM, NIPAM and ethyl cellulose
3.2 Delivery Device
In order to apply this technology in drug delivery applications, a reservoir drug delivery device has been
designed with the polymer membrane serving to regulate flow of fluid in and out of the device. The
reservoir portion of the device functions primarily to store drug (see Figure 5). The resulting device can
regulate the release of drug or other active agents over a period of several days. Currently, there are
two designs for a drug delivery device that incorporates this polymer membrane:
1. An all-membrane device - i.e. drug encapsulating spheres made from the polymer membrane
2. A device with the polymer membrane on the ends of a drug reservoir
All prototypes of the drug delivery device to date have been created using the second design since all-
membrane devices are much harder to produce, would require advanced equipment such as casting
molds, and may have increased safety concerns around leakage of drug into the body. Since the
polymer membrane is a tough and flexible film when hydrated, it can be cut or molded into any shape
and still retain all of its physical properties. Given the membrane's flexible nature and mechanical
strength, it is feasible that an eventual device could be composed entirely of the membrane.
The current version of the device consists of a biocompatible silicone tube (drug reservoir) with the
polymer membrane glued to the ends, into which a drug solution or super-saturated drug slurry can be
injected (See Figure 5). Silicone tubing was chosen for the drug reservoir because it is commonly used in
FDA-approved devices such as catheters and peristaltic pumps. Additionally, selective heating of the
device has been demonstrated in prototypes by gluing two aluminum foil rings separated by a gap to the
outside of the silicone reservoir (See Figure 6). For optimal biocompatibility, however, future prototypes
will have gold foil rings glued to the inside of the reservoir. The foil rings serve as the device's antenna to
focus microwave radiation inside the device. This allows the contents of the drug reservoir to be
selectively heated, which then induces heating of the membrane from inside the device. This method
allows for drug release from the device without unnecessarily heating the surrounding tissues.
Additionally, the membrane's ethyl cellulose backbone and the silicone drug reservoir help insulate the
increased temperature of the drug in the reservoir from the body. The glue currently used to join the
membrane to the silicone tubing is a cyanoacrylate-based, low viscosity, quick-drying, adhesive that is
similar to Superglue. Since cyanoacrylate adhesives are known to induce an inflammatory response and
break down into toxic components such as formaldehyde, later versions of the drug delivery device will
have to use a different type of adhesive"1 .One idea for solving this problem is to use a laser to melt the
membrane onto the silicone tubing.
Top membrane
Bottom membrane
Drug reservoir
(currently filled with sodium fluorescein)
Figure 5: Prototype of drug delivery device
(Prototype Dimensions: silicone tubing = 1cm length, 3/8" OD; membrane = 1 cm diameter)
Foil antennaGao
Front membraneBack membrane
Figure 6: Prototype of delivery device with antenna
3.3 Progress to Date
Currently, a number of biocompatibility studies and drug studies have been conducted to show that the
polymer membrane will not induce a significant immune response and that the drug delivery device is
capable of exhibiting selective release of drug. One of the biocompatibility studies performed involved
creating spherical nanoparticles out of the polymer membrane and injecting them intramuscularly into
rats. Results from this study showed a minimal inflammatory response in the rat tissue. Additionally, the
polymer membrane has also been implanted underneath the skin of rats and extracted after 4 days, 4
weeks, and 2 months. The results of this experiment showed that a very thin inflammatory capsule
forms around the membrane after four days, which becomes progressively more fibrotic over time (see
Figure 7). These results have been shown for replicate devices and are in line with what would be
expected from a biocompatible medical implant.
4 days post-implant 4 weeks post-implant
Figure 7: Biocompatibility of membranes implanted in vivo
Furthermore, a number of studies have been performed to show that flow of drug through the device
can be achieved and that this flow can be turned on and off. Flux of sodium fluorescein through two
devices was tested over 10 thermal cycles with cycle times of 24 hours. As can be seen in Figure 8, the
results show that drug was selectively released repeatedly over 10 cycles and that the flux results from
both devices were similar.
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Figure 8: Sodium fluorescein flux results from prototype drug delivery device
Additionally, flux experiments with the membrane only have shown that the membrane is capable of
selectively releasing three different compounds of varying sizes. These have included sodium fluorescein
(MW = 376 g/mol), which is a common model drug in drug delivery research; bupivacaine (MW = 288
g/mol), which is a commonly used local anesthetic; and fluorescently labeled dextran (MW =
4000g/mol), which is also commonly used as a model drug in research. This result is significant because
it verifies that the membrane is capable of delivering small molecule drugs as well as macromolecular
drugs such as insulin (MW 5733 g/mol). Finally, experiments were also performed that demonstrated
the ability of a microwave field to selectively heat the contents of the drug delivery device compared to
a fat mimic.
3.4 Novel Attributes of this Invention
As demonstrated in previous sections, this composite polymer membrane and drug delivery device has
unique properties that have never been reported before. Specific novel attributes of this invention
include:
1. An environmentally-sensitive composite polymer membrane that can be triggered "on" and
"off" by changing the temperature, heating with microwave radiation, or applying an oscillating
magnetic field.
2. A polymer membrane which can be made to exist in the "off" state at body temperature (37"C)
and physiological saline concentrations, but that can be triggered "on" by moderate
temperatures (41"C -42°C) not injurious to surrounding cells under physiological conditions.
3. An implantable device (with or without the capacity for refilling) consisting of a flux-controlling
polymer membrane and a drug reservoir with a high concentration of an active ingredient. The
device can be triggered externally to selectively release the reservoir contents at a desired rate
and temporal pattern.
4. An implantable delivery device which also serves as a microwave antenna to facilitate selective
heating of the device contents (to externally trigger release of the reservoir contents) without
significantly increasing the temperature of the surrounding tissues.
3.5 Competing Technologies
To date, there have not been any publications that show a polymer-based drug reservoir that can be
turned on and off repeatedly. The closest technology is a glucose-sensitive polymeric membrane
developed by Dr. Kai Zhang and Dr. Xiao Yu Wu at the University of Torontol2. This technology, however,
is only suitable for insulin delivery and is currently not suitable for implantation. Additionally, the
technology is self-regulating (controlled by the interstitial fluid blood glucose level) and thus cannot be
controlled remotely.
Moreover, although other laboratories have used magnetic-sensitive polymers in research, most of
these technologies involve polymers with a magnetic particle at its core instead of having magnetic
particles distributed throughout the polymer 13 14, 15. As the core is heated, the polymer collapses to
release drug. The main drawback to this approach is that the delivery device can only be used once since
the polymer cannot be reformed to its original form after heating. Other labs have tried using
polyelectrolyte multilayers to entrap ferrofluids or to deposit surface-modified magnetic nanoparticles
as a shell on a thermoresponsive microgel core'6 . Once again, however, these approaches only allow for
one time use since they cannot be opened and closed repeatedly.
Additionally, the field of wireless or remote-controlled drug delivery is still in its infancy. The only
technologies that have gained significant traction in this field are based on microelectromechanical
systems (MEMS). MEMS technology is based on micro-chips with gold-coated silicon reservoirs whose
coatings dissolve when a voltage is applied17 . Two pioneers in the field of MEMS for use in drug delivery
are Dr. Michael Cima and Dr. Robert Langer at MIT. Their work in MEMS has been spun out into a
startup drug delivery company called MicroCHIPS 18. MicroCHIPS has developed an implanted microchip
and wireless technology that it is able to actively control drug release over a prolonged time (See Figure
9). Currently, the company is developing a parathyroid hormone technology to treat osteoporosis. The
advantages of MEMS are their low power consumption, reproducibility, cost-effectiveness, precise
controllability, and miniaturization capability19.Additionally, MEMs-based drug delivery devices allow
for a sudden burst release of drug and allow multiple drugs to be administered at one time. The
downside, however, is that the technology is much harder to refill. Microchip-based technologies are
also significantly harder to gain acceptance by the medical community since there are safety concerns
around implanting a microchip with internal electronics. On the contrary, the remote-controlled drug
delivery technology described in this thesis should have many of the same advantages of MEMS with the
added benefit of being easier to refill and not microchip-based. The two properties of MEMs devices
that this technology would not have, however, are the ability to deliver a burst release of drug and to
deliver multiple drugs at the same time.
Figure 9: Millimeter-sized reservoirs in prototype MicroCHIPS drug delivery device20
3.6 Key Technical Barriers
In order to bring this technology to the point in the commercialization roadmap where preclinical trials
can commence, a number of key technical barriers must first be overcome. One of these barriers is the
biocompatibility of the device in small animals. Currently, only the polymer membrane has been tested
in vivo and has shown promising results. In order to move into preclinical trials on large animals,
however, the entire device will need to be tested in small animals first to ensure that it does not elicit an
immune response.
Additionally, the remote triggering feature of the device needs to be tested in animals. So far, remote
triggering has only been tested in vitro on a lab bench. In order to show proof of concept of the remote
triggering device, the lab plans to load a barbiturate into the device and implant it into a mouse. The
goal here is to show that the application of electromagnetic radiation externally causes drug to be
released, which will be indicated by the mouse falling asleep. Conversely, removing the electromagnetic
radiation should result in the mouse waking up again.
Another key barrier is the design of the device. As mentioned, there are two ways to make the polymer
membrane into a device, but so far, experiments have only been conducted on the device with polymer
membranes on the ends of a drug reservoir. Additional work needs to be done to determine how to
create a device mold to cast an all-membrane device and also how to use a laser to attach the
membrane onto the silicone tubing. Another key issue with the device design is making the device easy
to refill with drug.
Based on discussions with laboratory members and other scientists, it is estimated that it will take
approximately three to four years to address the aforementioned technical hurdles and begin preclinical
testing. This estimate, however, assumes that there will be enough funding and personnel to carry out
the research. It also assumes that there will be no major unforeseen technical problems in the
development of this technology. Further details on the funding and personnel requirements can be
found in Section 8.1.
4. POTENTIAL APPLICATIONS & MARKET ANALYSIS
4.1 Potential Applications
The potential applications for a broad technology such as this are very extensive and exciting. Unique
polymers have transformed the world we live in and are increasingly being used every day to solve a
host of problems. Possible applications for this novel technology that have been identified include:
Medical Applications
* Remote-controlled drug delivery - A handheld device could be used to stimulate drug release
allowing for patient-mediated control. Alternatively, a closed loop monitoring or dosing device
could be designed.
* Transdermal drug delivery -A heating pad or built-in electronic heater may be used to open the
pores of the membrane and transfer drugs or other therapies across the skin.
* Microfluidics - Polymer membrane could be used as a valve to create a programmable
microfluidics separation device.
* Medical diagnostic tools - A continuous monitoring tool could be designed consisting of an array
of wells, each separated by the polymer membrane. Upon external triggering, the membrane of
each well would open sequentially and take in external fluids. A reaction would then occur
within the reservoir. This tool would allow one to build an analyte curve.
Non-Medical Applications
* Shipping quality control - Device could be mounted on temperature-sensitive shipments and
loaded with a dye to test whether the product inside was exposed to extreme temperatures.
* Breathable clothing - Body heat could activate clothing to open nanopores to allow for
improved air permeation (i.e. sports clothing)
Based on interviews with venture capitalists, scientists, and individuals working in industry, drug delivery
devices seem to be the most suitable application for this technology. The ability to trigger a thermal and
magnetically sensitive membrane externally holds promise for the creation of remote-controlled drug
delivery devices. These devices could potentially allow for patient-mediated control or even closed loop
monitoring and dosing. Additionally, the drug delivery market looks encouraging for the following
reasons:
1. Demonstrated clinical need
As will be shown in sections 4.2 -4.5, all of the drug delivery applications identified represent
serious chronic clinical conditions, most of which have few effective therapies.
2. Large market
All of the identified'applications represent multi-billion dollar markets with thousands of
suffering patients.
3. Area of greatest expertise
Dr. Kohane and Dr. Hoare developed this technology with drug delivery applications in mind and
both scientists have considerable experience in this field.
4. Area of greatest competitive advantage
Drug delivery applications can specifically exploit this technology's novel technical features such
as thermal and magnetic sensitivity and external triggering of a polymer-based device.
Although this polymer technology could be used to develop non-medical products in significantly less
time and at much lower cost, non-medical applications do not look favorable because they have lower
margins, a lower barrier to entry, and because the Langer laboratory's expertise is in developing
polymer-based technologies for drug delivery applications.
Within the field of drug delivery, there are four large unmet chronic clinical conditions that have been
identified as possible target markets for this technology. These applications are:
1. Pain Management - delivery of local anesthetics to specific locations to treat chronic pain
2. Cancer - local delivery of chemotherapy or other cancer-fighting therapies to a tumor site
3. Epilepsy - closed loop monitoring & dosing device for preventing seizures
4. Insulin Delivery (Diabetes) - repeatable non-injection insulin dosing for treating diabetes
4.2 Market Analysis: Pain Management
Unmet Need
The field of pain management includes both acute and chronic pain and has had a severe impact on
society both in terms of quality of life for patients as well as economic expense. It is estimated that
direct and indirect costs associated with pain add up to almost $100 billion every year and account for
over 50 million lost days of work21. Pain management has become such a big problem that the U.S.
Congress has declared this decade as the Decade of Pain Control and Research. Currently, chronic pain is
suffered by more than 50 million people in the US, while acute pain due to surgery or injury affects
almost 25 million people21
This externally-triggered drug delivery technology could be combined with a handheld activation device
to allow for patient-controlled local delivery of drug to the site of pain. Such a device would allow
patients to receive pain relief on demand and modulate the intensity of their pain relief. In order to
prevent overuse, the device will be programmed during implantation to ensure that a safe amount of
pain medicine is delivered over a specific period of time regardless of how often the patient tries to
administer medication. Currently, a similar approach is used to prevent overdose in patient-controlled
anesthesia (PCA) devices22.The proposed patient-controlled drug delivery device would also take
advantage of a growing trend in pain management, which is that therapies are moving away from the
hospital and into homes21. Currently it is envisioned that this device would be filled with common forms
of anesthesia such as bupivacaine or one of its derivatives (lidocaine, tetracaine, or procaine) with or
without tetradotoxin (TTX). Although the device could be used to treat both chronic and acute pain, the
fact that it needs to be implanted within the body makes it a more logical treatment for patients
suffering from chronic pain.
Chronic pain can render individuals helpless and rob them of their ability to enjoy life, maintain
relationships and maintain a job. This can lead to severe economic distress as well as depression and
anxiety. Chronic pain can be nociceptive, neuropathic or both. Nociceptive pain, such as chronic lower
back pain, fibromyalgia, or rheumatoid arthritis, results from injury to muscles, tendons, ligaments, or
internal organs. Neuropathic pain, on the other hand, arises from abnormal nerve function or nerve
damage and can be caused by diseases such as Parkinson's disease or multiple sclerosis. Currently, most
patients living with chronic pain either take systemic pain killers, which essentially numb the body, or go
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to the doctor for injections. Even with these treatments, however, complete relief from chronic pain is
rare 2 .
Competition and Market Analysis
The pain management market can be divided into two parts: pharmaceuticals, which make up 90% of
the market, and pain management devices, which make up 10%. Pharmaceuticals are used to treat both
acute and chronic pain, whereas pain management devices specifically target chronic pain. According to
Frost & Sullivan, the U.S. pharmaceutical pain management market is estimated to reach revenues of
$35.8 billion in 2009 and the device market is estimated to reach $3.98 billion21'24. The treatment option
that our technology would compete most directly against is intrathecal pumps and patient-controlled
anesthesia (PCA), which reached revenues of $240.1 million in Europe in 2006 and has been growing
rapidly at a compound annual growth rate (CAGR) of 13.6%24. Intrathecal pumps are used specifically for
injecting pain management drugs into the intrathecal space surrounding the spinal cord. PCA consists of
a button attached to an intravenous line filled with drug and is used to deliver pain medicine directly
into the blood vessel. Although PCA is similar in function to the device that has been proposed in this
thesis, PCA can only be used in hospitals and is a systemic pain management solution rather than a local
one 22. Additionally, since this remote-controlled drug delivery technology can be used to treat chronic
pain throughout the body, and in hospitals as well as homes, the gross market size for our technology is
likely to be much larger.
The current line of commercial pain management products can be divided into three main categories:
oral medications, neurostimulators, and intrathecal pumps & PCA. Oral medications are pharmaceuticals
while neurostimulators, and intrathecal pumps & PCA are classified as pain management devices. As of
2002, the pain management pharmaceuticals market had 25 competitors with 165 different products,
many of which were traditional pain killers. On the devices side, there were 18 main competitors as of
2006. A summary of the four types of pain management solutions, their advantages and disadvantages,
and the market share leaders in each category can be found in Table 4 below.
More recently, a new type of device for pain management based on iontophoresis was approved in May
of 2006 and was introduced in Germany, the United Kingdom, and Ireland in January 200825,26. This
device, called IONSYS and developed by Johnson & Johnson, uses a small electric charge to propel a high
concentration of a charged drug (fentanyl) transdermally. This device has been receiving a lot of
attention because it is the first needle-free, patient-activated analgesic system for treating pain. The
drawbacks of this new device, however, are that it is only for use in acute pain management in hospitals,
it delivers drugs systemically, and it can only deliver charged drugs. On the contrary, our technology
would have the benefits of being needle-free and patient-activated, and would also be able to treat
chronic pain locally and deliver any drug.
Table 4: Summary of competition in pain management market
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* Nonsteroidal anti-inflammatory drugs (NSAIDS)
** Transcutaneous electrical nerve stimulators (TENS), Spinal cord stimulators (SCS), Peripheral nerve stimulators (PNS)
4.3 Market Analysis: Cancer
Unmet Need
Cancer is a class of diseases caused by genetic mutations of cells in the body. Cancer can technically
occur within any tissue in the body and has three characteristics27:
1. Uncontrolled cell growth - Growth and division of cells beyond normal rates
2. Invasion - Intrusion and destruction of adjacent tissues
3. Metastasis (occurs sometimes) - Spread of cancerous cells to other areas of the body via blood
or lymph
Cancer is the second leading cause of death, accounting for nearly one-quarter of all deaths in the
United States. Worldwide, cancer was responsible for 7.6 million deaths in 2007. Approximately one in
two American men and one in three American women will develop cancer sometime over the course of
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their life. The most frequently diagnosed cancers are prostate cancer in men and breast cancer in
women. Although some cancers, such as melanoma, breast cancer, and prostate cancer, are commonly
cured, many other forms of cancer have no form of effective treatment. The five-year relative survival
rate for common types of cancer in the U.S. can be seen in Table 5 below 28. Current treatments for
cancer depend on the stage of the disease as well as the location and size of the tumor. Common
treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and monoclonal
antibody therapy.
Table 5: U.S. five-year cancer relative survival rates (1996-2003)28
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This novel drug delivery technology would increase the cancer survival rate by providing surgeons with a
device that could be implanted during a biopsy and release a baseline quantity of drug locally to the site
of a tumor. The amount of baseline release would be controlled by the design of the polymer
membrane. Additionally, the device could be triggered to deliver a higher dose of cancer-fighting drugs
as necessary. Treating cancer in this manner could potentially reduce the toxicity of chemotherapy drugs
to surrounding healthy cells. Alternatively, this device could be implanted following tumor removal and
deliver drugs to ensure that non-excised tumor fragments are killed. This would also minimize the
amount of extra healthy tissue that would need to be removed. Minimizing the loss of healthy tissue
during tumor removal is often a primary concern of surgeons, especially when working in sensitive areas
such as the brain.
Competition and Market Analysis
Worldwide, the market for cancer therapies is currently estimated at $34 billion per year, with the
United States accounting for 60% of the world market 29, 30. This number is expected to grow to between
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$55 billion and $70 billion by 2010. Three reasons why analysts are expecting large increases in growth
include:
1. A number of drug candidates have shown clinical success using a variety of novel ways to target
cancer cells.
2. The continued success in a number of technological innovations including proteomic and
genomic platforms.
3. The failure of traditional techniques such as chemotherapy and radiation to increase life
expectancy rates in many cases of cancer.
These factors combined with the high incidence of cancer have spurred a large influx of research and
development (R&D) investment into the field of cancer therapies. In 2005, there were 500 potential
cancer drugs in clinical trials and it is expected that 50-55 new cancer products will be launched within
the next five years 3o,31. Some of the areas that are expected to see the most development can be seen
in Table 6 below.
Table 6: Areas of greatest development in cancer therapies30
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4.4 Market Analysis: Epilepsy
Unmet Need
Epilepsy is one of the most common serious neurological disorders and is a chronic condition
characterized by reoccurring unprovoked seizures, which can last from a few seconds to a couple of
minutes. These seizures are caused by a malfunction of the brain's electrical system, which leads to the
brain discharging electrical energy continuously instead of in a controlled manner. This rapid firing can
lead to a surge of energy through the brain resulting in unconsciousness, contractions of the muscles, as
well as a range of uncontrolled movements. Currently, there is no cure for epilepsy. This is partly due to
a poor understanding of the disease and its causes. Despite recent advances in epilepsy research,
doctors are still unable to determine the cause of epilepsy in seven out of ten patients. Nevertheless,
medications and some other treatments have been shown to prevent seizures32.
The envisioned solution for utilizing this technology to treat epilepsy is a closed loop monitoring and
dosing device for preventing seizures. This device would be implanted in the brain and would both
monitor the brain for abnormal activity as well as deliver anti-epileptic drugs as necessary. The device
would be constructed such that it can be easily refilled through the scalp similar to the way that the
reservoir of a Ventriculo-Peritoneal (VP) shunt can be accessed to retrieve cerebrospinal fluid (CSF) in
patients with hydrocephalus (See Figure 10).
Note: Reservoir for testing VP Shunt
or retrieving CSF can be felt as a small
bubble under the scalp33.
Figure 10: Insertion of Ventriculo-Peritoneal (VP) shunt for draining cerebrospinal fluid (CSF)3
In order to create the detection system for this proposed device, collaboration with scientists
specializing in neuroengineering would be necessary. Currently, preliminary discussions have been
initiated with Dr. Edward Boyden at MIT. Dr. Boyden's laboratory has developed a way of detecting
seizures up to five hours beforehand by studying the localized changes in cell firing that temporally
precede seizures. Based on discussions with Dr. Boyden, it is believed that his technology could be
combined with this drug delivery technology to create a device that would both detect and treat
seizures.
Competition and Market Analysis
Epilepsy and seizures are known to affect over 3 million people in the U.S. with approximately 200,000
new cases each year. Additionally, it is estimated that these seizures result indirect and indirect costs of
$12.5 billion per year 32. Treatment options can be divided into three categories: oral medication
(drugs), neurostimulators, and surgery. Oral medication has been the most popular treatment for
seizures and has been shown to give 50% of patients control over their seizures. Currently, there are 17
drugs available to treat epilepsy, many of which are already off-patent. 75% of the global anti-epileptic
drug market is controlled by five pharmaceutical giants: Pfizer, Johnson & Johnson, Abbott Laboratories,
GlaxoSmithKline (GSK), and Novartis35.
In the medical device market, there is currently only one company, called Cyberonics, that has
developed a vagus nerve stimulator device. This lack of competition makes the epilepsy medical device
market seem like a very attractive option for this technology. Additional companies are, however,
expected to emerge in the next three to five years. Based on market forecasts, it is estimated that, by
2013, anti-epileptic drug sales will reach $13 billion worldwide and device sales (VNS Neurostimulator)
will reach $160 million in the U.S.35, 36.A summary of the three treatment options for epilepsy, their
advantages and disadvantages, and the market share leaders in each category can be found in Table 7
below.
Table 7: Summary of competition in epilepsy market
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4.5 Market Analysis: Insulin Delivery (Diabetes)
Unmet Need
Diabetes is a chronic disease in which the body fails to produce or process insulin, thereby resulting in
high blood glucose levels, also known as hyperglycemia. Elevated glucose levels over a long period of
time can lead to angiopathy and eventually cardiovascular disease, coronary artery disease, stroke, or a
number of other diseases. In fact, over 65% of people with diabetes end up dying from heart disease or
stroke. For this reason, diabetes is often termed the "silent killer". From 2005 - 2007, the total
prevalence of diabetes increased 13.5%. Today, it is estimated that there are approximately 23.6 million
people (adults and children) suffering from diabetes in the U.S. alone, representing 8% of the
population. Additionally, 24% of these people are unaware that they even have the disease37 .
Diabetes can come in three forms: type 1, type 2, and gestational diabetes. A description of the three
types can be found in Table 8.
Table 8: Summary of the three types of diabetes37
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Currently, there is no cure for diabetes and most treatments for the disease involve a combination of
lifestyle changes (i.e. diet, exercise, weight loss) and use of insulin and/or synthetic insulin analogs. For
the past 80 years, the majority of diabetes patients have received their insulin by injection with a
needle. This process is both tedious and painful and has significantly impacted patient compliance. To
solve this problem, this technology could be used to create a remote-controlled device for delivering
insulin. This device would be similar to that described for the pain management application in that it
would be combined with a handheld activation device to allow patients to deliver insulin at home
without the hassle of needles. The only difference is that the device would be filled with insulin instead
of a pain relief drug. Additionally, with the development of glucose sensing technologies, it is possible
Type 1
that this device could be combined with a glucose sensor to create a closed-loop insulin dosing device in
the future.
Competition and Market Analysis
It is estimated that 7.45 million patients will need insulin by 2010. In 2003, the insulin delivery devices
market had sales of $1.26 billion in the U.S. and was growing at a CAGR of 14%. In Europe, the insulin
delivery devices market was $599 million with a CAGR of 22.9%38.
Because of the very large market opportunity, the insulin delivery market is very crowded with
competitors. In 2003, there were 14 companies specializing in insulin delivery and there were 27
different products on the market38. These products can be classified into four categories: oral delivery,
pump delivery, injectables, and future technologies. A summary of the four types of insulin delivery,
their advantages and disadvantages, and the market share leaders in each category can be found in
Table 9 below.
A key development in this industry was the approval of Exubera® by the Food and Drug Administration
(FDA) in January 2006. Exubera*, a joint development effort between Pfizer and Nektar Therapeutics,
was the first inhaler-based insulin delivery device. Analysts had expected it to dominate the market with
sales between $1 billion to $4 billion because it was easy to use and did not require any injections with a
needle, a common complaint by patients. However, a bulky design and a high price point resulted in
Exubera® only achieving sales of $12 million for the first 9 months of 2007. As a result, Pfizer eventually
pulled Exubera®out of the market, losing $2.8 billion in the process"
Table 9: Summary of competition in insulin delivery market 38'39'40
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Market Entry Recommendation
As mentioned, one of the primary complaints of patients with diabetes is the constant need to inject
insulin with a needle. The proposed remote-controlled insulin delivery device could offer a solution to
this problem since it would allow patients to receive their insulin in a simple, easy, needle-free manner.
Although this application for our technology is promising, the large number of competing companies as
well as current and future technologies has shown that there is significant risk in pursuing this market.
Additionally, the fact that this device needs to be implanted could severely hinder market adoption
since most patients prefer to avoid surgery due to high upfront costs and the chance of complications.
Furthermore, the Exubera® example has shown that customer preferences are fickle and that it is very
hard to successfully penetrate the insulin delivery market. As Doug Levinson, a partner at Flagship
Ventures, mentioned, "the insulin delivery devices market has become a graveyard of failed products
and technologies, and many companies have started pulling out of it" 41.As a result of these findings, it is
recommended that commercialization efforts focus on the first three applications (pain management,
cancer, and epilepsy) while the insulin delivery application remains a viable alternative.
MethodAdvantag I Disadvantages I Major Players
4.6 Competitive Advantage (Pain Management, Cancer, & Epilepsy Applications)
Of the four possible target markets identified for this technology, three of them present compelling
market opportunities where this technology would have a distinct competitive advantage. These three
markets are pain management, cancer, and epilepsy. The advantages of this technology over existing
technologies in each of these markets are identified in the following three sections.
Pain Management
The main competitive advantage of the proposed drug delivery device for pain management
applications is that it allows patients to receive pain relief on demand that can be adjusted to suit their
needs. Essentially, a patient could turn their pain on and off and receive surgical quality anesthesia at
their home. Since chronic pain is often intermittent and anesthetics or high doses of pain relievers can
inhibit motor function, the ability to modulate the intensity of one's pain relief is indispensible. For
instance, if a patient was sitting in the living room and needed to go to the bathroom but had a sudden
pain attack, he could turn up the amount of pain relief so that the pain was bearable but motor function
was retained. Thus, this device could potentially allow patients suffering from crippling pain to return to
a semi-normal life and take part in the activities they love.
Another key advantage is that this device would allow for local delivery of drug to the site of pain. As
mentioned, most current pain management solutions are systemic. Systemic drugs are released into the
blood stream and travel throughout the body. A small amount of the drug goes to the brain, causing a
patient to feel groggy. With prolonged use, this will also lead to dependence on the drug. Additionally,
since drugs affect every tissue and organ differently, systemic drugs that travel throughout the body
naturally cause many unwanted side effects. At high doses, systemic drugs can also cause a loss in motor
control. On the contrary, local delivery of drugs will likely have fewer side effects and will need smaller
doses for pain relief since the drug is being delivered to a specific area in the body.
Cancer
As mentioned, a remote-controlled chemotherapy delivery device would minimize the damage of
chemotherapy drugs to healthy cells during cancer treatment and could also minimize the removal of
healthy tissue. Additionally, implanting the device at the site of the tumor should increase the
effectiveness of chemotherapy agents. It could also decrease the amount of chemotherapy drugs
needed to treat a tumor, which would further reduce toxicity to healthy cells. Minimizing damage to
healthy tissue is of utmost importance since damaged tissue causes side effects and weakens the body's
immune response to infection. Common side effects of chemotherapy include nausea and vomiting,
hair loss, and fatigue42
In addition to delivering chemotherapy agents, this device could be used to deliver other cancer-
fighting drugs locally to the site of a tumor. It could also be customized to deliver different drugs
depending on the patient and the type of cancer. Furthermore, implanting the device during a biopsy or
following tumor removal eliminates the need for additional surgery. This would reduce costs for the
patient as well as reduce the risk of complications. All of these factors combined could result in a more
effective treatment of cancer, reduced treatment times, and reduced recovery times.
Epilepsy
As in the other two applications, this proposed drug delivery device would allow for local delivery of
drug, in this case anti-epileptics, and would have the same benefits over current systemic drug solutions.
In addition, local delivery would allow one to administer much more drug to the brain than would be
normally tolerated by the body if delivery was systemic. This advantage could significantly increase the
efficacy of current anti-epileptic drugs by increasing the percentage of patients who gain control over
their seizures to over 50%.
Additionally, this technology could eliminate current problems around noncompliance with prescribed
anti-epileptic drugs since it is an automatic monitoring and dosing device. Currently, noncompliance has
been estimated at 60% and studies have shown that it is a critical issue in the long-term management of
epilepsy. These studies have also claimed that noncompliance may be the single most common reason
for anti-epileptic drug failure43
As in the other applications, this device could be used with any anti-epileptic drug and could be
customized to deliver different drugs depending on the patient and the severity of the disease. Given
that many first line therapies are already off-patent, this customization could be done at very little extra
cost by using generic anti-epileptic drugs. Doing so would also significantly reduce the cost for patients
to refill the device.
5. INTELLECTUAL PROPERTY
5.1 Current Status of Intellectual Property
Currently, Dr. Daniel Kohane and Dr. Todd Hoare have submitted an invention disclosure to the MIT
Technology Licensing Office who, in turn, has submitted a provisional patent application to the United
States Patent and Trademark Office (USPTO). The provisional patent application covers the design and
fabrication of externally-triggered thermosensitive membranes and their possible commercial uses
including drug delivery.
5.2 Competing Patents
A comprehensive search of patents in the United States and worldwide was conducted to determine
whether a patent can be filed around this technology and to analyze the competition in this field. The
patent search included examining patents related to thermal and magnetically sensitive membranes,
magnetic heating, microwave heating, and pulsatile drug release devices. Based on this examination, six
patents were indentified that use similar components, have similar triggering mechanisms and/or have
similar applications. A complete listing of these patents can be found in Table 10 below. Nevertheless,
none of these patents present a serious threat to the commercialization of this technology.
Table 10: Competing patents
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A short description of each competing patent and its relevance to this technology is included in the
following paragraphs. The differentiating factors between the claims in the patent and this invention are
also highlighted.
Area of Competing Interest: Temperature sensitive polymer membranes
US 6,565,872 Polymeric system for drug delivery and solute separation
The composite polymeric system described in this patent is similar to the glucose-sensitive polymer
membrane developed by Dr. Zhang and Dr. Wu that was mentioned in section 3.5. The claims in this
patent, however, are broader and are based on a later publication in Biomaterials entitled "Temperature
and pH-responsive polymeric composite membrane for controlled delivery of proteins and peptides"44 .
The invention described in this patent is a polymer that can respond to various stimuli such as
temperature and pH changes. The patent's claims include methods to make this stimuli-responsive
polymer into a swellable hydrogel and into a non-swellable hydrophobic polymer.
U6,58
US 2007/0148437 A
(Spition)WO/2003/101486
The method for fabricating the composite polymeric system claimed by Dr. Zhang and Dr. Wu is similar
to that used to construct the thermal and magnetic sensitive polymer described in this thesis. A few key
differences are that Dr. Zhang and Dr. Wu do not incorporate a ferrofluid or another nanoparticle within
their membrane. In the case that the methods are too similar, however, Dr. Kohane and Dr. Hoare do
not anticipate that it will be difficult to alter their methods to avoid patent infringement.
Area of Competing Interest: Magnetic heating
US 2007/0148437 Al Thermosensitive, Biocompatible Polymer Carriers with Changeable Physical
Structure for Therapy, Diagnostics and Analytics
This U.S. patent reports methods for fabricating biocompatible, thermosensitive polymers that can be
heated using a high-frequency magnetic alternating field. The invention also claims that inductive
heating can be used to rupture liposomes, microspheres, capsules, or other particulate drug delivery
systems. Rupturing of these systems would then trigger a burst release of bioactive substances (i.e.
drug).
The disadvantage of the described drug delivery system is that it only allows for a single release of drug
within a short period of time. Once the particulate is ruptured, all of the encapsulated drug will be
released at once. Secondary releases of drug are not possible in this proposed system without injecting
new drug-filled particulates into the body. On the contrary, the device proposed in this thesis would
allow for triggered drug release the can be administered repeatedly. Additionally, this proposed device
could be refilled as necessary.
Area of Competing Interest: Microwave heating
WO/2003/101486 Thermosensitive Polymer Carriers Having a Modifiable Physical Structure for
Biochemical Analysis, Diagnosis, and Therapy
This world patent, by the same inventor as U.S. patent application US 2007/0148437 Al, also describes
thermosensitive polymer carriers based on N-isopropylacrylamide and acrylamide derivatives, which can
be inductively heated by a magnetic alternating field. In this invention, however, claims have been made
for polymer compositions in which magnetic heating induces a phase transition (either swelling or
shrinking) within a polymeric gel or microparticle. This phase transition reduces the flow of drug at high
temperatures.
Dr. Kohane and Dr. Hoare's proposed device is different from that claimed in this invention because it
allows for positive thermosensitive control (flux of drug increases at high temperatures) instead of
negative control. Positive thermosensitive control is generally more useful in drug delivery applications
since temperature increases can be used to initiate drug flow. In a negative control device, temperature
decreases would be needed, which are much harder to achieve.
Area of Competing Interest: Microwave heating
HU 20060003B Membrane for use in e.g. selective binding, separation, purification, comprises
2007-780415/200773 nano- or micro-sized gel particles having dimensions instantly changed by
environmental parameters
The inventors of this technology have received Hungarian patent protection and recently applied for
World Patent protection in 2007. Although the text of the issued patent is currently only available in
Hungarian, the abstract mentions the ability to "control the material transport through a membrane by
changing the permeability of the membrane... instantly by environmental parameters, e.g. temperature,
pH, ionic strength, salt concentration, composition of the mixture, magnetic or electric field, microwave,
ultrasound or light so that pore sizes of the channels can be controlled within a wide range." The
composition of the membrane and methods for fabrication are currently unknown.
Although it is hard to tell whether this patent competes with our technology since the text is in
Hungarian, it is possible that this patent has claims for using magnetic heating to control thermal and
magnetically sensitive membranes. The patent's abstract also mentions that one of the intended uses
for this technology is for medical applications. Despite this fact, the polymer membrane described in this
thesis has unique features regarding how the membrane is fabricated to maximize the degree of
predictability of thermal and magnetic triggering. Nevertheless, further investigation of this patent is
necessary.
Area of Competing Interest: Pulsatile drug release devices
US 6,491,666 Microfabricated devices for the delivery of molecules into a carrier fluid
This U.S. patent, assigned to MicroCHIPS, Inc. in 2002, makes claims to a microchip-based drug delivery
device with reservoirs containing molecules for release. The device allows for active or passive
controlled release of these molecules. Possible applications that have been claimed include systems for
intravenous administration of drugs and drug eluting stents.
Implantable drug releasing microchips are the closest competing technology capable of pulsatile drug
release responses. However, unlike the technology described in this thesis which releases contents with
zero-order release kinetics, these microchips provide true pulsatile delivery since all reservoir contents
are released instantly upon ablation of the membrane. As mentioned in section 3.5, there is also some
resistance to using implantable powered devices when alternative approaches exist.
Area of Competing Interest: Pulsatile drug release devices
US 7,226,442 Microchip reservoir devices using wireless transmission of power and data
This invention describes the same microchip as US Patent 6,491,666 but makes claims to methods for
wirelessly powering and/or communicating with the implanted microchip to release the contents of the
microchip's reservoirs. The patent describes a microchip system capable of wirelessly receiving power
from a remote transmitter. The microchip also has a telemetry system that allows for wireless transfer
of data between the device and a remote controller
The differences between the technology described in this patent and Dr. Kohane's and Dr. Hoare's
technology are the same as those discussed in the previous section.
5.3 Intellectual Property Strategy
The results of the comprehensive search detailed in the previous section, indicate that many novel
aspects of this thermal and magnetically sensitive drug delivery technology have not been reported in
scientific literature and have not been patented. Firstly, there have not been any reports in the
literature demonstrating a thermal and magnetically triggerable membrane that can function correctly
under tolerable physiological conditions (zero or minimal release at 37 °C and maximum release at
temperatures below 42 "C). Additionally, the ability to create an implantable drug delivery device with
an antenna that can focus microwave radiation is also a novel concept. Moreover, with the possible
exception of Hungarian patent HU 20060003B, there do not seem to be any patents surrounding the use
of magnetic heating to control temperature sensitive membranes. It is possible that each of these
unique properties could be patented.
Intellectual Property Strategy
In order to commercialize this technology, a broad range of patents will need to be filed to protect the
designs for both the polymer membrane and delivery device. A series of patents around a particular
technology serves both to protect the invention as well as intimidate others from entering the same
field. Where possible, the patents around the polymer membrane will need to make claims to an
extensive range of compositions for temperature and magnetically sensitive polymer membranes,
methods for preparing these polymer membranes, methods for their production and purification, and
all possible end-use products incorporating such membranes. Similar patents will also need to be filed
for the delivery device. As the status of the technology advances, additional patents will also need to be
filed to ensure that new designs, formulations, and/or applications are protected.
Bringing this invention to market will also require that the technology leaves the academic setting at
some point, either by licensing the technology to another firm or developing a startup company around
the technology. Alternatively, a hybrid strategy could be pursued where a startup company is formed
around certain applications of the technology (i.e. drug delivery) and other applications are licensed to
outside companies (i.e. breathable clothing and shipping quality control). As is customary for MIT
inventor-backed companies, if Dr. Kohane and/or Dr. Hoare decide to form a startup company, they will
have first preference to license these technologies from MIT. Licensing patents from a university
typically incurs royalty payments if the technology makes it to market. Sometimes the university will
take a small equity stake in the startup company as well. Although royalties and equity are negotiated
on a case by case basis between the inventors and the university, typical royalty rates range from 0.5%
for minor improvement patents to 8% for composition patents45
6. BUSINESS MODEL
6.1 Paths to Commercialization
As mentioned previously, two main paths are typically employed when moving a technology from an
academic setting to a commercial setting. These options are licensing the technology outright or
building a company around the idea. The advantages of licensing the technology from the beginning are
that, once the technology is licensed, it requires very little effort on the inventor's part. Essentially it
allows one to return to his/her occupation and move on to develop new ideas. Licensing a technology
also requires very little capital other than what is spent trying to make the technology look attractive to
potential licensees. As a result, there is very little risk involved with licensing other than the fact that the
technology may never make it to market. With little risk, however, also comes little reward since
royalties on licensed technologies are typically very small (typically under 8%) and significant revenue is
only realized if the product is sold at high volumes. Finding a licensee can also be very troublesome. All
of these reasons explain why less than 3% of patented ideas make it to market through licensing
agreements46
Another option is to build a company around a technology. There are many different ways to build a
startup company around a technology, all of which require a lot of dedication, hard work, and tolerance
for risk. One possible option is to raise enough money to develop the technology and product in-house
and then partner with a larger firm for sales, marketing, and distribution. Partnership could also come
earlier in the lifecycle of the company to help fund technical development or clinical trials. Alternatively,
the founders could raise a lot of capital and develop, market, and sell the technology on their own. This
is the most risky option for building a company and also the most dilutive since investors will take
control of a large portion of the company in return for their funds. Another option is to start a company
and then merge with another startup company to leverage their expertise and develop products jointly.
Additionally, the founders could start a company that is a materials supplier and allow other firms to
develop and sell products using their materials.
6.2 Proposed Business Model
Based on discussions with scientists, entrepreneurs, and venture capitalists, it is proposed that this
technology be spun out into a medical device startup company since this is a common practice for
commercializing and creating value around a novel medical device technology of this nature. The Langer
laboratory also has significant experience in developing startup companies around novel drug delivery
technologies, with Dr. Langer having founded or co-founded over two dozen companies. It is important
to note that this technology is not ready for commercialization at its present state and that creation of a
company would only occur after significant development and successful completion of a number of
technical milestones.
The proposed startup company would be responsible for licensing the necessary patents from MIT,
determining a target market for this technology, and identifying specific applications for its use. The
company would also continue developing the remote-controlled drug delivery technology and finalize
the design for the drug delivery device. Additionally, the startup would conduct preclinical trials on small
animals and prepare for preclinical trials on large animals as well as human clinical trials (see section 7.1
for more details on clinical trials). Completing these milestones would require the company's founders
to incorporate, rent office and lab space, hire employees, and raise capital. The funding required for this
startup and possible sources of investment are explained in sections 9.1 and 9.2.
Upon successful completion of preclinical trials on small animals, it is proposed that the startup
company outsource preclinical trials on large animals to a biological testing service and retain a contract
research organization (CRO) to perform human clinical trials. It is recommended that clinical trials be
outsourced to a CRO because clinical studies are complicated processes involving several steps, namely,
study design, setting up patient recruitment centers, enrolling patients, carrying out the study, and
performing a follow-up on treated patients. Given that 10-25% of clinical trials fail due to flawed design
and clinical trials are extremely expensive, it is important that all efforts are made to minimize errors47
Additionally, a small startup company does not have the employees, laboratory space, or equipment to
run preclinical or clinical trials on its own (Both biological testing services and CROs have their own
resources and conduct studies in their own labs). In order to manufacture devices for clinical trials and
product launch, it is recommended that a contract manufacturer be retained. The reason for using a
contract manufacturer is that it is much too expensive for a startup company with little cash and a high
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cost of capital to build its own plant. It is also important to make sure that the product successfully
completes clinical trials and is able to penetrate the market before making a large fixed investment in a
manufacturing facility. Upon successful market entry, however, it would be wise for the startup
company to move forward with constructing a manufacturing facility because economies of scale would
make this option more profitable than outsourcing to a contract manufacturer.
Additionally, upon receiving FDA approval for the device, it is proposed that the startup company
partner with a larger firm for sales and distribution and be jointly responsible for marketing. The
benefits of a partnership would include the ability to leverage the larger company's existing customer
relationships and experienced sales force. Utilizing the partner's sales force will also eliminate the high
up-front costs of recruiting and hiring experienced sales people. It would also help to mitigate risk in
case the product is not as successful as predicted. Additionally, partnering will allow the startup
company to attain a broad market penetration in less time than trying to do sales and marketing on its
own. This type of partnership is very common for small medical device companies and provides a
number of benefits to both parties involved
The following sections will assume that the business model proposed above is chosen as the course of
action for this technology. All estimates and calculations will be based on the assumption that a startup
company is formed, clinical trials and manufacturing are outsourced, and that the startup company will
partner with a larger firm for sales and distribution at the appropriate time.
6.3 Value Chain
In order to understand how this technology will be commercialized and enter the market, it is important
to understand the value chain for such a device. As can be seen in Figure 11, the value chain for this
technology consists of five major players. At the beginning of the chain is the raw materials supplier who
the startup company will interact with in order to buy the core materials for manufacturing the polymer
membrane and the drug delivery device. Currently, all materials for the polymer membrane are bought
from Sigma-Aldrich, but this could change depending on who is the lowest cost provider.
Our startup company would comprise the second link in the value chain, which is where the raw
materials are turned into the final product. As mentioned previously, manufacturing of the drug delivery
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device will initially be outsourced to a medical device contract manufacture to keep costs low. One
possible contract manufacturer is The Tech Group. This company is a Class II and Class III medical device
contract manufacturer that specializes in the production of polymer-based drug delivery devices among
other healthcare and consumer products4 8. Additionally, preclinical and clinical trials will be outsourced
to a biological testing service and a CRO respectively. One of the most reputable testing services is
Charles River Laboratories in Wilmington, MA. One possible CRO that could be used is Covance, which is
one of the largest CROs in the world.
The next link in the value chain is the hospital. The hospital is responsible for deciding whether a device
should be purchased. In making purchasing decisions, the hospital will consult physicians, who have the
final decision on whether to use the device in a patient. One of the critical steps for this startup
company will be interacting with both the hospital and the physicians and convincing them to purchase
this product. In order to make sure this process goes smoothly, it makes most sense to partner with a
larger medical device firm for sales and distribution as mentioned previously. Doing so will allow a small
startup to leverage a larger company's experienced sales force as well as their preexisting relationships
with hospitals and physicians.
The final link in the value chain is the patient who is the end user of the device. Contrary to conventional
thought, the patient has very little input into the value chain since the decision on whether to use the
device is usually made by the physician. The patient can, however, refuse to have the device implanted
and opt for a different treatment instead.
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Figure 11: Value chain
6.4 Key Decision Makers
In the healthcare industry, there are three key decision makers who control adoption of a product into
hospitals. These decision makers are:
1. Physicians
2. Hospitals
3. Insurance providers
Physicians
As mentioned, physicians have the final decision on whether to use a medical device in a patient. The
physician's chief concern is in improving patient outcomes. In order to learn about the latest products,
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physicians typically attend conferences, keep up to date with the latest publications, and speak with
peers and company sales personnel. If they are interested in a new product, they will suggest it to the
hospital.
Hospitals
Before a new medical device can be implanted, it must first be approved by the hospital. Hospitals
evaluate new products using formalized processes and cross-functional committees. These committees
are concerned, first and foremost, with a product's efficacy, but they are also concerned about cost.
Oftentimes, the committees will balance these two factors in comparison to alternatives. Each hospital
receives a lump sum payment from insurance companies for a given procedure, regardless of how much
it actually costs. Thus, it is critical that the amount of reimbursement covers the cost of purchasing and
implanting the device49
Insurance Providers
Insurance providers are most interested in improving clinical outcomes and minimizing healthcare costs.
As mentioned, insurance providers reimburse hospitals with a lump sum payment for a particular
procedure. These reimbursement rates are set by the Centers for Medicare and Medicaid Services
(CMS), which is the largest health insurer in the US. The CMS is required to reimburse procedures that
become standard of care. Reimbursement is initiated with the issuance of a Diagnosis Related Groupings
(DRG) codesO
7. DEVELOPMENT PLAN
As mentioned previously in Section 3.6, there are a number of key technical hurdles that need to be
overcome before this technology is ready to leave the academic laboratory and begin the pathway to
commercialization. Once this technology is ready to be commercialized, however, the two largest
remaining obstacles are regulatory approval and manufacturing.
7.1 Regulatory Approval
Preclinical Testing
In order to bring this remote-controlled drug delivery device to market, FDA approval will need to be
obtained. Since this product contains both a medical device component (the drug delivery system) and a
drug component, it will be regulated as a drug /device combination product. Combination products are
subject to intense regulatory examination since the combination of a drug and a device poses additional
safety and efficacy concerns compared to devices or drugs alone. Combination products can be assigned
to one of three centers within the FDA: the Center for Drug Evaluation and Research (CDER), the Center
for Biologics Evaluation and Research (CBER), or the Center for Devices and Radiological Health (CDRH).
Assignment of the center that will have the lead responsibility for reviewing a combination product
submission depends on the primary mode of action (PMOA) of the product. The lead center usually has
jurisdictional responsibility as well (See Table 11) 51. In order to get a formal decision on which center will
have jurisdictional responsibilities, a request for designation (RFD) can be submitted to the Office of
Combination Products within the FDA. Based on the FDA's description of the roles of each of the three
centers and an interview with Dr. Kristina Lauritsen from the Office of Combinational Products, it has
been determined that this product would most likely be considered an implantable drug delivery system
and assigned to the CDER for lead review (see Table 12)52. It is also likely that the CDRH will take part in
the review as well. The differences between the CDRH and CDER review teams can be seen in Table 13.
Table 11: Combination product responsibilities for lead FDA center5 3
Table 12: Combination-product examples and FDA center jurisdiction5 3
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Table 13: Comparison of CDRH and CDER combination product review teams53
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Before human clinical trials can commence, preclinical trials on animals must be completed and an
investigational new drug (IND) application must be filed and approved by the FDA. Prior to submitting an
IND application, there is the option to submit a pre-IND application to the FDA. The applications are
followed by a pre-IND meeting, which allows personal interaction with and feedback from an FDA
review team.
An IND application must contain three main test results. The first is in vivo pharmacokinetic studies,
which should quantify the duration of drug exposure. These studies involve giving live animals the
intended dose of drug and then gathering pharmacokinetic data on how long the drug remains in the
animal's body. Another test result the IND application requires is toxicity studies with follow-up
evaluations to show preliminary evidence of drug safety. The third test result needed is biocompatibility
data showing that the drug and device do not interact chemically or physically with each other in an
adverse way. Some of the common preclinical testing inadequacies can be found in Table 143. In
addition to these tests, information is needed on the chemical composition of the drug and
manufacturing methods. Detailed protocols of proposed human clinical trials and descriptions of the
qualifications of clinical investigators are also requireds4
Table 14: Common preclinical testing inadequacies for combination product submissionss53
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Clinical Trials
Receiving FDA approval for a drug-device combination is a very complicated process and depends
heavily on the application being targeted and the drug being used. Unlike all new drugs which go
through the same set of Phase I, Phase II, and Phase III clinical trials, drug-device combinations can go
through a variety of clinical trials or directed studies depending on requirements decided by the CDER,
and to a lesser extent the CDRH. For combination devices using different forms of an existing drug, CDER
chemistry reviewers typically expect a full characterization of the following:
1. Drug substance (or active ingredients providing therapeutic benefit)
2. Excipients (or substances other than active ingredients)
3. Final drug product (or final dosage form containing the active ingredients and excipients)
Full characterization is defined by the CDER as testing results from three components: chemistry,
manufacturing, and controls. Definitions of these components can be found in table 15 below. In
addition to this data, the CDER also requires testing results on drug stability throughout the life of the
combination product, drug quality, kinetic drug release and method of sterilizationss
Table 15: Definition of chemistry, manufacturing, controls testing components ss55
Co n D itio & P
If the formulation of the drug being used in the combination device is very similar to its approved form,
then it is possible to bypass many of the aforementioned testing requirements. In some cases, only one
or two directed studies may be required to show safety, show primary efficacy, and make an argument
for bioequivalence56.This fact will likely be very advantageous to the pain management application since
the formulation of drug loaded into the delivery device would be exactly the same as what is currently
used to deliver local anesthetics. The only differences would be that the device reservoir would contain
a higher concentration of drug to minimize size and would deliver less drug since it is at the site of pain.
Following successful completion of required studies, a New Drug Application (NDA) will be submitted to
the FDA for approval.
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7.2 Manufacturing
Current Manufacturing Process
The current process for manufacturing the thermal and magnetically sensitive polymer membrane and
delivery device is very crude. Since laboratory research only requires very small amounts of the
membrane, the copolymer microgel component of the membrane is made in a 500 mL round-bottom
flask and the other components are added to the microgel by physical mixing. The resulting mixture is
then placed in a Tupperware container and allowed to dry by slow evaporation of the ethanol in the
mixture. Following these steps, the membrane is cut to the proper dimensions and then glued to the
silicone tubing by hand to complete the drug delivery device.
Manufacturing on a Commercial Level
In order to bring this technology to market, the process for constructing the remote-controlled drug
delivery device must be scaled and standardized to allow for efficient, reliable, and safe mass
production. Manufacturing the drug delivery device on a commercial scale will involve four key steps,
starting with production of the thermal and magnetic sensitive polymer. Polymer production will most
likely be performed using an automated batch reactor and the process would be similar to current
methods used to manufacture polystyrene latex for ink toner cartridges. A batch reactor consists of
three main components: a tank made of stainless steel (other materials can also be used), an agitator
consisting of a centrally mounted driveshaft with impeller blades, and heating/cooling coils or jackets5 7.
A schematic of a batch reactor can be seen in Figure 12.
Heating /
Cooling Jacket
Driveshaft
- Stainless Steel Tank
Impeller Blades
Figure 12: Schematic of batch reactor with single external cooling jacket5 7
Manufacturing would need to be done under inert conditions and it is estimated that a complete
polymer could be made in four hours. A majority of this time will be spent polymerizing the polymer, a
process that takes between two and three hours. One advantage in manufacturing this polymer is that,
since all components are water soluble, cleaning and maintenance of a batch reactor would be very
simple, allowing for high throughput.
Following production, the resulting polymer will need to be purified. Currently, the polymer is purified
using dialysis. On a commercial scale, however, it may be more cost effective and quicker to purify the
polymer using a centrifuge. Centrifugation is possible because the polymer product is composed of
phase-separated particles. Once the polymer has been produced and purified, fabrication of the device
can begin. As mentioned previously, the final product may be an all-membrane device, but will most
likely be a device with polymer membranes on the ends of a drug reservoir. If the final product is an all-
membrane device, then it will be made by casting the membrane in a device mold. If the product is a
drug reservoir with polymer membranes on the ends, however, laser etching will most likely be used to
melt the membrane onto the drug reservoir. The final step in manufacturing this device will be filling the
drug reservoir with drug, which will be done using a syringe. A summary of the manufacturing steps can
be seen in Table 16.
Table 16: Manufacturing steps for making remote-controlled drug delivery device
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Outsourcing Manufacturing
As mentioned in Section 6.2, manufacturing will initially be outsourced to a contract manufacturer with
experience in producing polymer-based drug delivery devices because it is too expensive for a medical
device startup company to build its own plant. Since this product is intended for used as a medical
device, the selected contract manufacturer must be FDA registered and current Good Manufacturing
Practice (cGMP) compliant. GMP regulations guarantee that products are consistently produced in a
controlled environment and require that all aspects of medical device manufacturing are documented.
The regulations also require that manufacturing and testing equipment has been qualified to produce
medical products and that all operational methods and systems have been validated. It will also be
important to choose a contract manufacturer that is ISO 9001 certified. ISO certification means that a
company has been independently audited and certified to meet the International Organization for
Standardization (ISO) manufacturing standards.
7.3 Development Timeline
Based on discussions with Dr. Daniel Kohane, Dr. Todd Hoare, and a number of seasoned entrepreneurs
with experience in commercializing medical device technologies, it is estimated that it will take
approximately twelve years before this product reaches the market5o 58. Thus, product launch can be
expected to occur sometime in 2020. The first three years of development will be spent on academic
research in Dr. Kohane and Dr. Hoare's laboratories. During this time, the laboratories will work on
resolving the key technical barriers discussed in section 3.6. These include device design and refinement
as well as basic biocompatibility and device performance tests on small animals. Following these tests, a
company will be formed around this technology and an additional two years will be spent licensing
patents, determining target markets, creating a development plan and finalizing the product design.
Preclinical trials are expected to commence in 2013. Preclinical testing will take approximately 18
months and will include in vivo pharmacokinetic (PK) tests, toxicity studies and additional
biocompatibility studies. Preclinical trials on large animals will likely be performed at this time as well
followed by an IND filing to the FDA. After successful preclinical trials, FDA clinical trials will begin in
2015. Although the exact studies required by the FDA are unknown, a generous estimate is that it will
take approximately five years to conclude clinical trials, after which an NDA will be filed to the FDA. In
parallel with clinical trials, the startup company will negotiate with larger medical companies to find a
partner for sales and distribution. Assuming the product is approved by the FDA, a marketing strategy
will also be put in place to coincide with an expected product launch date sometime in 2020. A complete
technology development timeline can be seen in Figure 13.
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Figure 13: Technology development timeline
8. COST MODEL
8.1 Pre-Commercial Costs (Academic Laboratory)
As mentioned earlier, it is estimated that three more years of further research and development is
needed before this technology is ready to be commercialized and a startup company can be formed.
Based on the experiments both scientists have already planned and the additional technical hurdles that
still need to be crossed, it is estimated that it will take approximately $635,000 in additional investment
over three years before this technology is ready to be moved out of the academic setting. A breakdown
of the future investment needed is outlined in Table 17.
Table 17: Future investment needed to reach preclinical trials
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8.2 Development Costs
Material Cost
The current version of the remote-controlled drug delivery device in the laboratory has five major
components: ethyl cellulose, ferrofluid, NIPMAM-NIPAM copolymer microgel, cyanoacrylate glue, and
silicone tubing. The first three components are used to make the thermal and magnetically sensitive
polymer membrane, and the last two are used to make the device's body. As can be seen in Table 18
below, very little of these raw materials are needed to make the device. Based on quoted costs from
Sigma-Aldrich, the approximate cost of raw materials is around $0.49 per device. Since the actual device
may vary in size, however, a conservative estimate would be under $5.00 per device. Regardless, this
analysis shows that the raw materials will be a small component of the actual cost of this device.
It is important to note that the actual commercial device is likely to have more components. Two key
components that were left out of this cost analysis are the drug that will go into the device and the
external component of the device that will trigger drug release. The cost of the drug will depend heavily
on which drug is used, whether the drug is still under patent, and what type of licensing or bulk
purchasing deal can be negotiated with the drug manufacturer. Even with these two additional
components, however, the final cost of raw materials is still likely to be small compared to some of the
other costs associated with bringing this device to the market such as manufacturing and regulatory
costs.
Table 18: Material costs for remote-controlled drug delivery device s9
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Manufacturing Cost (Outsourced)
Since the final design of the drug delivery device has not been completed, it is very difficult to estimate
the approximate costs for manufacturing this device. Additionally, due to economies of scale,
manufacturing costs for this device could vary widely depending on the number of devices that are
produced. Based on an interview with Dr. Edward Parsons, Head of Imaging at Epix Pharmaceuticals, it is
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estimated that manufacturing for a medium scale-up will cost between $400,000 and $600,000 per
yearso. It is assumed that a medium scale-up would be sufficient capacity for clinical trials and product
launch.
Regulatory Cost (Outsourced)
Without a definite decision by the CDER as to what type of data is required to receive FDA approval for
this device, it is difficult to determine what clinical trials and other studies will need to be performed.
Human clinical trials are very expensive. Setting up a single patient recruitment center can cost between
$250k and $1M for a Phase I drug trial and even more for Phase II or III trials. Additionally, costs per an
enrolled patient can range from $10,000 to $36,000 (See Table 19)47.
Table 19: Per patient costs for clinical trials in six disease areas47
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The clinical condition being targeted also plays a major role in determining regulatory costs since clinical
trials for some conditions require longer follow-up studies than others. Additionally, successful clinical
outcomes (defined as a p-value or statistical significance level of 5% or higher) can be easier to prove in
some diseases than others. For example, a chronic pain trial will require a very large patient population
to achieve statistical significance since feelings of pain are often very subjective. Based on discussions
with Dr. Edward Parsons, who has experience in designing clinical trials for pharmaceutical products, it is
estimated that clinical studies may take as long as five years to complete and can cost up to $15-20
millionso
Startup Costs
As can be seen in Table 20, the estimated startup cost for the first year of operation is around $2.3
million. The largest component of this analysis is the operating costs. The operating costs assume that a
Cardiovascular
Respiratory
25 weeks 6 $,000 $24,00
7,500 sq. ft. biomedical research facility with office and laboratory space is being leased in the Boston
area. Included in the operating costs are labor costs for 10 workers based on a representative mix of job
descriptions for a model biomedical company. These labor costs include a weighted average of yearly
earnings, annual base payroll costs, and fringe benefits. Additionally, the operating costs include utility
costs, equipment amortization costs, and corporate travel costs60
Table 20: Startup costs 60
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* Operating costs were scaled down from a report published by The Boyd Company, which estimated that
operating costs for a 75,000 sq. ft. biomedical research facility in the Boston area with 100 people would be
approximately $10,632,657
8.3 Pricing
In order to compensate for the added risk and expense associated with regulatory approval, medical
devices and drugs can often be sold at very high prices and are extremely profitable. The average gross
margin of medical device companies and branded pharmaceutical companies was around 70% in 2001
and was relatively steady for the five years before then61' 62. The following analysis estimates a possible
selling price for this remote-controlled drug delivery device applied to the treatment of epilepsy. As
stated in section 4.4, there are approximately 200,000 new cases of epilepsy per year. Assuming that
this device would attain a very low 1% penetration in its first year, this would mean that 2,000 of the
devices would be sold.
In this pricing analysis, it is assumed that 2,000 devices is equivalent to a medium scale-up of
production. From section 8.2, contract manufacturing costs for a medium scale-up were estimated at
$600,000. The material cost per device without drug and an external triggering component was
estimated to be $5 in section 8.2. Additionally, the external handheld triggering component was
estimated to be an extra $5, making the total cost of the device $10. This gives a total material cost of
$20,000 for 2,000 devices without drug. Furthermore, it was hypothesized that a generic anti-epileptic,
such as gabapentin (800 mg), would be used in this device. In tablet form, gabapentin costs
approximately $549.22 for a year's supply (see Table 25). Assuming that this device is filled with a year's
supply of gabapentin, the total cost of drug for 2,000 devices is $1,098,440. Adding all of these costs
together gives a total cost of production of $1.72 million or $859 per patient. Finally, a 70% gross margin
was assumed based on the medical device and pharmaceutical gross margins mentioned in the previous
paragraph. Taking these assumptions into account, the selling price for this device would be
approximately $2,864. A summary of this pricing analysis and the assumptions made can be found in
Table 21 and 22.
Table 21: Summary of pricing analysis with cost breakdown
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As can be seen in the price comparison tables for common pain management, cancer, and epilepsy
therapies, an estimated selling price of $2,864 is well under the costs of current medical devices treating
the same conditions (See Tables 23, 24, and 25). Current pain management and epilepsy devices can
cost between $20,000 and $50,000, and some cancer therapies, such as Erbitux and Avastin, can cost
over $100,000 for a year's supply. This comparison also shows that the $2,864 proposed price could be
increased generously if necessary to account for unforeseen increases in manufacturing, development,
or marketing costs following product launch. Additionally, given the enormous benefits of this remote-
controlled drug delivery device over current competing devices, it is likely that this product could
command a price premium over competing devices.
Table 23: Price comparison of various pain management therapies63' 64'65
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Table 24: Price comparison of various cancer therapies66, 67,68,69, 70
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Table 25: Price comparison of various epilepsy therapies63' 71
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9. INVESTMENT
9.1 Investment Required
To date, funding for this project has come from an R01 National Institutes of Health (NIH) Research
Project Grant (#GM073626) and a National Science Foundation (NSF) grant. Dr. Hoare also recently
received an NSERC Discovery Grant that will provide funding for some equipment and a postdoctoral
student. Although these grants will cover a portion of the estimated $635,000 needed for academic
research, more funding will be required. Currently, both scientists are in the process of writing and
applying for additional grants to fund this research.
Based on the cost model for this technology, the total investment required to bring this technology from
the time it moves out of the academic lab to the completion of preclinical trials (a period of four years) is
in the order of $17 to $18 million. A breakdown of the expenses can be seen in Table 26 below.
Table 26: Total investment needed to bring technology to completion of preclinical trials
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*Assumes only differences from startup costs are that the company grows by 5 employees every year (and operating,
computer, and office furniture costs are scaled appropriately) and R&D costs increase by $500,000 every year.
**Assumes preclinical trials comprise a tenth of the $20M clinical trial cost
In order to provide a comparison, the investment history for MicroCHIPS is displayed in Table 27. As
mentioned earlier, MicroCHIPS is currently working on a microchip-based remote-controlled drug
delivery device. Currently, MicroCHIPS is in the preclinical stage of development and has raised $51
million in capital. MicroCHIPS has estimated that it needs significantly more money than the $17.4
million estimated for this startup because it spent a number of years working on its technology platform
before focusing on a specific product 56 . Nevertheless, this comparison shows that the funds needed to
market this technology are not completely out of line with competing technologies working towards
similar goals. Additionally, significant challenges or a desire to build a platform around this drug delivery
technology could result in the need for additional capital as well.
Table 27: MicroCHIPS, Inc. investment history72
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9.2 Sources of Funding
Funding for startup companies can come from a number of different sources and depends heavily on
the stage of growth the company is in, the amount of money needed, and the applications and markets
targeted. Some of the most common sources of investment include:
* Friends and Family
* Gap Funds
* Government Grants
* Gifts and Venture Philanthropy
* Angel Investors
* Venture Capital
* Corporate Investment
Friends and Family
Occasionally, friends and family will invest in a startup because they believe in the idea, helped develop
it, or because they want to show their support and can afford to do so. Typically, this investment is easy
to obtain and acts as seed money to get the startup off the ground. On the downside, however, if the
startup fails, it can create a rift between close friends and/or family members.
Gap Funds
Gap funds provide money to help transition a technology between academia and formal investment by a
venture capital firm, corporation, or some other means. Gap funds exist at many major universities but
can exist outside of the university setting as well. One example of this type of fund is the Center for
Innovative Technology's (CIT) GAP fund, which makes small equity investments in Virginia-based
technology and life science companies73
Government Grants
Government grant programs have historically been the lifeblood for academic research laboratories, but
certain government programs help businesses get off the ground as well. The most well-known of these
is the Small Business Innovation Program (SBIR), which was formed in 1982 to encourage
entrepreneurship and stimulate the U.S. economy. Federal SBIR research and development grants are
intended to protect small businesses and help fund the critical startup and development stages of a
company. Funding is provided by 11 federal departments and agencies and is awarded in three phases:
* Phase I (Startup Phase) - Awards of up to $100,000 for approximately 6 months are intended to
help explore the feasibility of an idea or technology.
* Phase II - Awards of up to $750,000 for approximately 2 years are intended for research and
development work.
* Phase III - No funds are given. Small businesses must find private funding or other non-SBIR
federal grants.
In order to receive SBIR funding, a startup company must have at least 50% ownership by American
citizens, be independently operated, and be for-profit. Additionally, the company cannot be bigger than
500 people and must employ the principal researcher that invented the idea or technology74
Gifts and Venture Philanthropy
Gifts and venture philanthropy are an excellent source of funds for a startup because they often provide
money without taking an equity investment or requiring the startup to pay it back. These funds can vary
in amount from a few hundred thousand to a few million dollars and are typically provided by
foundations or families of patients. Examples of foundations that provide funds include the Epilepsy
Foundation of America, the Muscular Dystrophy Association, and the Bill & Melinda Gates Foundation.
Angel Investors
An angel investor is a wealthy individual who provides funding for a startup company. Oftentimes, angel
investors are former executives or successful entrepreneurs themselves. Angel investors typically invest
small amounts of capital ($100,000 - $500,000) during the seed round of a startup company. Recently,
angel investors have been organizing themselves into bands of angels to pool funds so that they can
make larger investments. Angels will typically take equity or convertible debt in return for their
investment.
Venture Capital
Venture capital is the most common source of funds for a startup company. Venture capital funds have
access to large pools of capital and are capable of making follow-on investments as a company grows.
Venture capital funds will typically invest between $1.5 million and $25 million over the life of a
company and expect high returns on the order of 5 to 15 times their investment within 3-7 years. The
advantage of receiving venture capital funding is that it validates a technology and can often drive
market acceptance. Venture capital funds can also leverage their experience in building companies as
well as their network of personal contacts to help a startup company grow. The drawback of venture
capital money, however, is that venture capital firms take a large equity stake in return for their capital.
As a result, venture capital firms will typically control a majority of the startup post-funding, leaving the
founders with very little decision power over the company they started7s
9.3 Comparables
The potential markets being targeted by this technology represent large unmet needs that have a high
potential for growth. Consequently, there have been a number of lucrative exit opportunities for those
who have invested in medical device companies in these fields. Table28 below shows a few of the exits
for medical device companies with products in the pain management and epilepsy markets. These exits
demonstrate that the high risk in developing medical device companies is accompanied by the potential
for high reward.
Table 28: IPO and M&A comparables36'76'77
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10. RISK ASSESSMENT
Commercialization of this remote-controlled drug delivery device poses a number of risks, both from a
technical standpoint, as well as an operational, regulatory, and marketing standpoint. These challenges
could lead to additional funds being required or investments being entirely wasted if the company is
unable to launch a successful product on the market and have it be widely adopted. The key technical
barriers that need to be resolved before commercialization can commence were outlined in section 3.6
and include proving biocompatibility and the remote triggering capabilities in vivo, finalizing the design
of the device, and determining how to make the device easy to refill.
Once the aforementioned technical challenges are solved and the technology is moved out of the
academic laboratory and into a startup company, there is a whole new set of technical hurdles to be
overcome. Some of the major risks that need to be resolved are to successfully demonstrate that the
remote-controlled drug delivery device is effective in improving clinical outcomes, is reliable, and is safe
for use in humans. One aspect of the technology that may cause significant problems is the remote-
control aspect of the device. Wireless medical devices are currently an upcoming and unproven field,
and thus significant difficulties could arise. It is also important that the external remote control does not
influence other medical devices implanted in a patient's body, and that it only exhibits selective heating
of the polymer membrane within the device, and not surrounding tissues or organs. Although,
preliminary studies have shown that selective heating is possible, more rigorous testing will need to be
performed to ensure safety in humans.
With the commercial development of this technology, there is also significant risk involved in finalizing a
design that can be standardized so that manufacturing can be scaled up without affecting the quality
and reliability of the device. The largest development risk however, is obtaining FDA approval for this
device in the body. As mentioned, FDA approval will require a number of preclinical and clinical studies
and will incur significant expenses.
Once the product is approved, there are two major market risks. These are achieving patient compliance
and physician acceptance, and obtaining reimbursement from the CMS. With the first risk, there is a
possibility that patients and physicians will not like the idea of implanting a device for drug delivery in
the body. There is also the risk associated with convincing physicians that this device will improve
clinical outcomes. These market risks can be somewhat mitigated, however, by gaining the support of
key opinion leaders, publishing the results from clinical trials and additional studies that show the
efficacy of the product, and engaging with physicians at conferences to increase awareness and
promote the benefits of this product. A summary of the critical risks facing the development of this
technology can be found in Table 29 below.
Table 29: Critical risks facing successful commercialization of this technology
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11. CONCLUSIONS
The ability to initiate fluid release externally through a thermal and magnetically sensitive membrane
holds promise for the creation of novel, remote-controlled drug delivery devices. These devices would
allow for patient-mediated control or even closed loop monitoring and dosing. Furthermore, a remote-
controlled drug delivery device could potentially bring relief to thousands of patients suffering from
disabilities such as chronic pain, cancer, and epilepsy.
Although this drug delivery technology has a lot of potential, a number of technical challenges need to
be overcome before the invention is ready to leave academia and begin the path to commercialization.
Once commercialization does begin, however, the largest risk facing this technology is FDA approval.
This remote-controlled drug delivery technology will be regulated as a drug-device combination by the
CDER and will require successful completion of IND and NDA applications. Another area of significant
risk is manufacturing this device efficiently and reliably. To mitigate these risks, both clinical trials and
manufacturing will be outsourced to experts.
An analysis of the intellectual property considerations around this technology has shown that there are
many novel aspects of this invention that could be patented and that this technology has significant
advantages over competing drug delivery technologies. To bring this technology to market, a business
model has been proposed that involves starting a company around the technology, outsourcing
preclinical and clinical trials to a CRO, outsourcing manufacturing to a contract manufacturer, and
partnering with a larger company for sales and distribution. This strategy maximizes the potential for the
technology to succeed commercially. Using this business model, it is estimated that this technology
could be launched as a commercial product by 2020.
As evinced by recent acquisitions of Advanced Bionics and Advanced Neuromodulation Systems for $740
million and $1.3 billion respectively, medical device companies in this field have been very profitable. A
study of competing products has shown that medical devices for treating chronic pain and epilepsy are
priced between $20,000 and $50,000 each with some cancer therapies reaching $100,000. Cost
calculations for this remote-controlled drug delivery device have shown that it could be priced
significantly lower than these current products and still be profitable.
Based on the intellectual property, regulatory, manufacturing, and marketing analyses in this thesis, it
has been concluded that this technology has vast potential to improve the lives of patients suffering
from chronic illnesses while remaining a viable business proposition.
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